NKTR
Nektar Therapeutics
60.40$
+5.9%
vs. previous close
Closing price · As of: Sep 28, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 14.2% | 14.8% | 18.3% | 9.9% | 2.0% | 18.6% | 12.7% | 24.4% | 23.5% | 40.7% | 31.2% | 0.0% | |
| 85.8% | 85.2% | 81.7% | 90.1% | 98.0% | 81.4% | 87.3% | 75.6% | 76.5% | 59.3% | 68.8% | 100.0% | |
| 73.6% | 79.2% | 123.2% | 87.2% | 33.5% | 379.1% | 267.3% | 392.8% | 237.2% | 126.7% | 122.8% | 212.4% | |
| 20.4% | 18.7% | 26.8% | 17.0% | 6.8% | 86.1% | 68.5% | 120.5% | 100.3% | 85.9% | 78.0% | 124.3% | |
| 94.0% | 98.0% | 150.0% | 104.3% | 40.3% | 465.3% | 335.7% | 513.3% | 337.5% | 211.8% | 175.7% | 336.8% | |
| -8.2% | -12.7% | -68.2% | -19.4% | 57.6% | -383.9% | -248.5% | -437.8% | -261.0% | -152.5% | -106.9% | -236.8% | |
| 19.3% | 16.9% | 25.5% | 13.3% | 3.6% | 40.4% | 24.3% | 46.4% | 31.4% | 28.1% | 28.6% | 47.4% | |
| -27.1% | -35.0% | -92.3% | -31.2% | 57.2% | -383.9% | -290.3% | -513.5% | -396.5% | -306.5% | -121.1% | -297.3% | |
| -0.3% | 0.2% | 0.5% | 0.2% | 0.1% | 0.5% | 0.3% | 0.5% | 3.5% | -0.2% | -0.2% | -0.2% | |
| -26.9% | -35.2% | -92.8% | -31.4% | 57.1% | -384.5% | -290.6% | -514.0% | -400.0% | -306.3% | -120.9% | -297.1% | |
| -1.4% | -12.7% | -58.8% | -13.8% | 61.5% | -333.9% | -257.9% | -453.2% | -351.8% | -269.8% | -88.1% | -248.1% |
Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.